In addition, an approach for Furin silencing, Vigil immunotherapy (GMCSF/bi-shRNA furin DNA engineered autologous tumor cell product) is expected in the future, as demonstrated in a phase I/II clinical trial for patients with advanced ovarian cancer [55, 56]. Here, FURIN is linked to neoplasm.